Clinical Trial Search

Primary: Percentage of Participants With American College of Rheumatology-ACR20 Response — 27.0; 50.6; 56.3 Percentage of participants — p=<0.0001

Primary: HbA1c Change From Baseline at Week 24 — 0.15; -0.49 Percent — p=<0.0001

Primary: HbA1c Change From Baseline to Week 24 — -0.56; -1.06 Percent — p=<0.0001

Primary: HbA1c Change From Baseline at Week 24 — 0.25; -0.44 Percent — p=<0.0001

Primary: Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET) — -8.52; -8.98; -10.02 Units on a scale — p=0.452

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -11.1; -12.3; -6.9 mmHg

Primary: Distribution of Visual Acuity in the Amblyopic Eye at 17 Weeks — 0; 0; 0; 0 participants

Primary: Number of Patients With Adverse Events — 16; 11; 51; 53 Participants

Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.292; 0.029 Proportion of participants — p=< 0.0001

Primary: Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites — 61.21; 61.04 Perfusion units

Primary: Progression-free Survival (PFS) — 33.6; 36.6 Weeks — p=0.8072

Primary: Daily Symptom Load — 1.25; 1.10; 1.32; 0.97 units on a scale

Primary: Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse) — 5.17; 2.00; 8.65; 4.00 Percentage of Events

Primary: Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal…

Primary: Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by…